Similar to wild-type (wt) Bcl-xL, anti-apoptosis-defective Bcl-xL mutants and an engineered Bcl-xL targeted to the nucleus can still promote tumor cell migration and invasion (Choi et al., 2016). This evidence concerns the gene BCL2L1 and neoplasm.